報價延遲最少15分鐘:2025/01/21 08:40 EST
|
|
|
|
|
||||||||||||
|
|
|
|
|
4.57 
|
|
|
| 價值評估 |
|
盈利(現時/預測)
-1.87/-2.17
|
|
企業價值
384.73M
|
| 資產負債 |
|
每股賬面淨值
7.30
|
| 現金流量 |
|
現金流量率
--
|
| 損益表 |
|
收益
425.17M
|
|
每股收益
11.28
|
|
同行比較
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
報價延遲最少15分鐘：2025/01/21 08:40 EST
同行比較之報價最少15分鐘延遲
|
業務概覽
|
|||
| Nevro Corp is a medical device company. Its key product is the HFX spinal cord stimulation (SCS) platform, which includes the Senza SCS system, an evidence-based neuromodulation system for the treatment of chronic pain. Senza generates electrical impulses to relieve pain. The system is implanted by physicians and controlled by patients. It consists of leads, a trial stimulator, an implantable pulse generator, surgical tools, a clinician laptop programmer, a patient remote control, and a mobile charger. The company generates the majority of its revenue in the United States. |